Kraft P, Beck M, Grimm A, Wessig C, Reiners K, Toyka K V
Neurologische Klinik und Poliklinik Würzburg mit Neuromuskulärem Zentrum, Josef-Schneider-Straße 11, 97080, Würzburg, Deutschland.
Nervenarzt. 2010 Oct;81(10):1218-25. doi: 10.1007/s00115-010-3008-6.
Symptomatic treatment of amyotrophic lateral sclerosis (ALS) is relevant in preventing complications and improving quality of life as long as curative therapies are still out of sight. About one third of ALS patients show disabling problems associated with dysarthria, dysphagia, sialorrhea, and a pseudobulbar affective disorder already in the early stages of ALS. A multidisciplinary approach is the cornerstone of symptomatic treatment of bulbar and pseudobulbar ALS features. Except for riluzole randomized controlled trials are lacking. Here, we review the current views with regard to epidemiology, pathophysiology, diagnosis, and practical aspects of treating bulbar and pseudobulbar symptoms.
在尚无治愈性疗法的情况下，肌萎缩侧索硬化症（ALS）的对症治疗对于预防并发症和提高生活质量至关重要。约三分之一的ALS患者在疾病早期就出现与构音障碍、吞咽困难、流涎和假性球麻痹情感障碍相关的致残问题。多学科方法是延髓和假性球麻痹ALS症状对症治疗的基石。除了利鲁唑外，缺乏随机对照试验。在此，我们综述了关于延髓和假性球麻痹症状的流行病学、病理生理学、诊断及实际治疗方面的当前观点。
